Search Results - "GOODIN, D. S"

Incidental MRI anomalies suggestive of multiple sclerosis : The radiologically isolated syndrome by OKUDA, D. T, MOWRY, E. M, BEHESHTIAN, A, WAUBANT, E, BARANZINI, S. E, GOODIN, D. S, HAUSER, S. L, PELLETIER, D

“…The discovery and broad application of MRI in medicine has led to an increased awareness in the number of patients with incidental white matter pathology in…”
Get full text

Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial by GOODIN, D. S, REDER, A. T, KNAPPERTZ, V, EBERS, G. C, CUTTER, G, KREMENCHUTZKY, M, OGER, J, LANGDON, D, RAMETTA, M, BECKMANN, K, DESIMONE, T. M

“…To examine the effects of interferon beta (IFNβ)-1b on all-cause mortality over 21 years in the cohort of 372 patients who participated in the pivotal…”
Get full text

Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome by OKUDA, D. T, MOWRY, E. M, CREE, B. A. C, CRABTREE, E. C, GOODIN, D. S, WAUBANT, E, PELLETIER, D

“…Technological advancements in neuroimaging and the increased use of these diagnostic modalities are responsible for the discovery of incidentally identified…”
Get full text

Genetic susceptibility to multiple sclerosis: interactions between conserved extended haplotypes of the MHC and other susceptibility regions by Goodin, D S, Khankhanian, P, Gourraud, P A, Vince, N

“…To study the accumulation of MS-risk resulting from different combinations of MS-associated conserved-extended-haplotypes (CEHs) of the MHC and three non-MHC…”
Get full text

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial by Ebers, G C, Traboulsee, A, Li, D, Langdon, D, Reder, A T, Goodin, D S, Bogumil, T, Beckmann, K, Wolf, C, Konieczny, A

“…BackgroundEvidence for efficacy of disease-modifying drugs in multiple sclerosis (MS) comes from trials of short duration. We report results from a 16 y,…”
Get full text

Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode by GOODIN, D. S, BATES, D

“…Multiple sclerosis is a chronic, demyelinating disorder of the central nervous system. It is characterised by progressive neurological disability, which is…”
Get full text

Evidence-based guideline update: Intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Clinical Neurophysiology Society by NUWER, M. R, EMERSON, R. G, GRONSETH, G. S, HARDEN, C. L, GALLOWAY, G, LEGATT, A. D, LOPEZ, J, MINAHAN, R, YAMADA, T, GOODIN, D. S, ARMON, C, CHAUDHRY, V

“…To evaluate whether spinal cord intraoperative monitoring (IOM) with somatosensory and transcranial electrical motor evoked potentials (EPs) predicts adverse…”
Get full text

Assessment : The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology by GOODIN, D. S, COHEN, B. A, O'CONNOR, P, KAPPOS, L, STEVENS, J. C

“…The clinical and radiologic impact of natalizumab (Tysabri) as therapy for multiple sclerosis (MS) is assessed. On the basis of Class I evidence, natalizumab…”
Get full text

Disease modifying therapies in multiple sclerosis: Report of the therapeutics and technology assessment subcommittee of the American Academy of neurology and the ms council for clinical practice guidelines by GOODIN, D. S, FROHMAN, E. M, GARMANY, G. P, HALPER, J, LIKOSKY, W. H, LUBLIN, F. D, SILBERBERG, D. H, STUART, W. H, VAN DEN NOORT, S

Get full text

Assessment: Transcranial Doppler ultrasonography: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology by SLOAN, M. A, ALEXANDROV, A. V, LEFKOWITZ, D, GOLDMAN, R. S, ARMON, C, HSU, C. Y, GOODIN, D. S, TEGELER, C. H, SPENCER, M. P, CAPLAN, L. R, FELDMANN, E, WECHSLER, L. R, NEWELL, D. W, GOMEZ, C. R, BABIKIAN, V. L

“…To review the use of transcranial Doppler ultrasonography (TCD) and transcranial color-coded sonography (TCCS) for diagnosis. The authors searched the…”
Get full text

Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence : Report report of the therapeutics and technology assessment subcommittee of the american academy of neurology by GOODIN, D. S, FROHMAN, E. M, HURWITZ, B, O'CONNOR, P. W, OGER, J. J, REDER, A. T, STEVENS, J. C

“…The clinical and radiologic impact of developing neutralizing antibodies (NAbs) to interferon beta (IFNbeta) while on this therapy for multiple sclerosis (MS)…”
Get full text

Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis by CREE, B. A. C, KHAN, O, HAINES, J. L, PERICAK-VANCE, M, DELOA, C, OKSENBERG, J. R, HAUSER, S. L, BOURDETTE, D, GOODIN, D. S, COHEN, J. A, MARRIE, R. A, GLIDDEN, D, WEINSTOCK-GUTTMAN, B, REICH, D, PATTERSON, N

“…African American (AA) individuals are thought to develop multiple sclerosis (MS) less frequently than Caucasian American (CA) individuals. To compare the…”
Get full text

HLA-DR2 Dose Effect on Susceptibility to Multiple Sclerosis and Influence on Disease Course by Barcellos, L.F., Oksenberg, J.R., Begovich, A.B., Martin, E.R., Schmidt, S., Vittinghoff, E., Goodin, D.S., Pelletier, D., Lincoln, R.R., Bucher, P., Swerdlin, A., Pericak-Vance, M.A., Haines, J.L., Hauser, S.L.

“…Models of disease susceptibility in multiple sclerosis (MS) often assume a dominant action for the HLA-DRB1*1501 allele and its associated haplotype (…”
Get full text

Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures by MOWRY, E. M, BEHESHTIAN, A, OKUDA, D. T, PELLETIER, D, WAUBANT, E, GOODIN, D. S, CREE, B. A, QUALLEY, P, LINCOLN, R, GEORGE, M. F, GOMEZ, R, HAUSER, S. L

“…Health-related quality of life (HRQOL) is reduced in multiple sclerosis (MS). It is unclear whether HRQOL is associated with white matter lesion burden or…”
Get full text

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology by GOODIN, D. S, ARNASON, B. G, COYLE, P. K, FROHMAN, E. M, PATY, D. W

“…Mitoxantrone is the first drug approved for the treatment of secondary progressive multiple sclerosis (SPMS) in the United States. This assessment considers…”
Get full text

The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology by FROHMAN, E. M, GOODIN, D. S, KACHUCK, N. J, LEVIN, M. C, PHILLIPS, J. T, RACKE, M. K, RIVERA, V. M, STUART, W. H, CALABRESI, P. A, CORBOY, J. R, COYLE, P. K, FILIPPI, M, FRANK, J. A, GALETTA, S. L, GROSSMAN, R. I, HAWKER, K

“…Advancements in imaging technologies and newly evolving treatments offer the promise of more effective management strategies for MS. Until recently,…”
Get full text

Clinical utility of surface EMG: Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology by PULLMAN, S. L, GOODIN, D. S, MARQUINEZ, A. I, TABBAL, S, RUBIN, M

Get full text

The epidemiology of multiple sclerosis: insights to a causal cascade by Goodin, D S

“…MS-pathogenesis involves both genetic-susceptibility and environmental determinants. Three (or more) sequential environmental-factors are implicated. The first…”
Get more information

The relationship of MS to physical trauma and psychological stress : Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology by GOODIN, D. S, EBERS, G. C, JOHNSON, K. P, RODRIGUEZ, M, SIBLEY, W. A, WOLINSKY, J. S

Get full text

Side effect profile of interferon beta-1b in MS : Results of an open label trial by NEILLEY, L. K, GOODIN, D. S, GOODKIN, D. E, HAUSER, S. L

“…To determine which patients are prone to side effects from interferon beta-1b and which side effects are most troublesome, we studied 72 patients with…”
Get full text